Butyricicoccus faecihominis: The Next Frontier in Microbiome Therapeutics
The era of "Next-Generation Probiotics" (NGPs) has arrived. While traditional probiotics like Lactobacillus and Bifidobacterium have paved the way, the pharmaceutical industry is now shifting its gaze toward commensal bacteria with potent, specific therapeutic mechanisms. Among these, Butyricicoccus faecihominis stands out as a premier candidate for treating inflammatory and metabolic disorders. As a specialized CRO dedicated to preclinical Live Biotherapeutics, Creative Biolabs believes that B. faecihominis represents a cornerstone in the future of microbiome medicine. Its ability to produce high levels of butyrate—a critical energy source for colonocytes and a potent anti-inflammatory mediator—makes it a high-value target for drug development.
Overview: What is Butyricicoccus faecihominis?
Butyricicoccus faecihominis is a butyrate-producing, Gram-positive, anaerobic bacterium belonging to the Clostridium cluster IV. It is an integral component of the healthy human gut microbiota. Unlike transient probiotic strains, B. faecihominis is often resident in the mucosa-associated microbiota, allowing it to interact closely with the host immune system.
Its primary biological significance lies in its metabolic output. As a major producer of butyrate (a short-chain fatty acid or SCFA), it plays a dual role:
Barrier Integrity: It strengthens the intestinal epithelial barrier by upregulating tight junction proteins (Claudins, Occludin).
Immune Modulation: It inhibits the NF-κB pathway, thereby reducing the production of pro-inflammatory cytokines.
Research indicates that the abundance of B. faecihominis is significantly reduced in patients with various chronic diseases, suggesting its potential as both a diagnostic biomarker and a therapeutic agent (bacteriotherapy).
Our Preclinical Service Portfolio
Working with strictly anaerobic, fastidious organisms like B. faecihominis requires specialized infrastructure and expertise. We offer an end-to-end service platform designed to de-risk your LBP development.
Microbiology & Strain Engineering
Isolation & Identification: We utilize high-throughput anaerobic culturing chambers to isolate specific strains from clinical samples.
Optimization: Development of industrial-grade culture media to maximize biomass and viability (CFU counts) of this difficult-to-grow anaerobe.
Genomic Characterization: Whole Genome Sequencing (WGS) to screen for antibiotic resistance genes and virulence factors (crucial for regulatory safety).
In Vitro Mechanism of Action (MoA) Assays
Before moving to animals, we validate the mechanism:
SCFA Profiling: Quantitative analysis of butyrate production using GC-MS.
Co-Culture Models: Utilizing Caco-2/HT-29 cell lines to measure epithelial barrier resistance (TEER) and tight junction protein expression after exposure to the bacterium or its supernatant.
Immune Assays: Macrophage and dendritic cell assays to measure the suppression of pro-inflammatory cytokines (IL-1β, IL-6, IL-12).
We provide validated animal models tailored to B. faecihominis research:
IBD Models: DSS-induced colitis and TNBS-induced colitis in mice/rats. Endpoints include disease activity index (DAI), colon length, and histology scoring.
Metabolic Models: Diet-induced obesity (DIO) mice and db/db diabetic mice. Endpoints include glucose tolerance tests (OGTT), insulin sensitivity, and lipid profiling.
Pharmacokinetics: Tracking the colonization and persistence of the strain in the GI tract using qPCR.
Product Offerings (For Research Use Only)
To support internal R&D at client sites, we supply high-quality biological materials derived from Butyricicoccus faecihominis, including live strains, inactivated strains, and genomic DNA.
This product contains high-quality, intact genomic DNA isolated from Butyricicoccus pullicaecorum Genomic DNA. It is a purified and ready-to-use DNA sample, ideal for a wide range of molecular biology applications, including PCR, qPCR, and Next-Generation Sequencing.
The pharmaceutical potential of B. faecihominis is currently being explored across several critical therapeutic areas. We have established specific models to validate efficacy in these domains.
1. Inflammatory Bowel Disease (IBD)
The strongest evidence for B. faecihominis lies in the treatment of Ulcerative Colitis (UC) and Crohn's Disease (CD). Preclinical studies have shown that oral administration of this strain can significantly attenuate symptoms in DSS-induced colitis models.
Emerging research links this strain to metabolic regulation. By modulating the gut microbiota profile, B. faecihominis can influence GLP-1 secretion and improve insulin sensitivity. It may also prevent high-fat-diet-induced metabolic endotoxemia by fortifying the gut barrier against LPS translocation.
3. The Gut-Brain Axis & Neurodegeneration
There is growing interest in the "psychobiotic" potential of butyrate producers. SCFA production can influence blood-brain barrier integrity and modulate neuroinflammation. Early preclinical data suggest potential applications in slowing the progression of neurodegenerative conditions like Parkinson's disease, where gut dysbiosis is a known precursor.
Our Advantages: Why Partner with Us?
Developing LBPs is distinct from small-molecule drugs. It requires a partner who understands the nuance of the microbiome.
Anaerobic Expertise
B. faecihominis is extremely sensitive to oxygen. We possess a fully anaerobic workflow (from isolation to lyophilization) that ensures strain viability—a common failure point in standard labs.
Regulatory Insight
We align our preclinical study designs with guidelines for Live Biotherapeutic Products, ensuring your data is submission-ready.
Omics Integration
We don't just look at the bacterium; we look at the ecosystem. Our services include 16S rRNA sequencing and metabolomics to understand how the introduction of B. faecihominis alters the host's overall microbiome and metabolic profile.
Customization
We do not believe in "cookie-cutter" science. We can develop germ-free mouse models or specific genetic knock-out models to test your specific hypothesis.
The potential of Butyricicoccus faecihominis to revolutionize the treatment of inflammatory and metabolic diseases is immense, but the path from concept to clinic is complex. The unique anaerobic requirements and the intricate host-microbe interactions demand a research partner with specialized tools and deep biological insight. By choosing our Microbiome Therapeutic Research Service, you are not just buying data; you are gaining a strategic partner dedicated to validating your asset's efficacy and mechanism.
Is Butyricicoccus faecihominis safe for human use?
While it is a commensal bacterium found in healthy humans, regulatory bodies require rigorous safety testing for LBPs. We offer comprehensive safety assessment services, including acute toxicity studies, translocation studies, and antibiotic resistance profiling to support GRAS (Generally Recognized As Safe) or IND determinations.
How do you maintain viability during animal dosing?
This is a critical challenge. We use specialized encapsulation techniques and anaerobic preparation buffers to ensure the bacteria remain viable during oral gavage. We also verify viability via fecal culturing post-administration.
Can you compare B. faecihominis efficacy against standard treatments (e.g., 5-ASA or Anti-TNF)?
Yes. We frequently run "head-to-head" or "adjunct therapy" studies where the microbiome therapeutic is tested alongside standard-of-care drugs to evaluate synergistic effects.
Do you offer GMP manufacturing?
Currently, we focus on Preclinical Research and pilot-scale production. However, we have partnerships with CDMOs to facilitate the tech transfer once your preclinical data is solid.
Online Inquiry
For Research Use Only. Not intended for use in
food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
